BCDA — BioCardia Income Statement
0.000.00%
Last trade - 00:00- $11.56m
- $10.61m
- $0.06m
Annual income statement for BioCardia, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.145 | 1.01 | 1.35 | 0.477 | 0.058 |
| Cost of Revenue | |||||
| Gross Profit | 0.141 | 1.01 | — | — | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 15.2 | 13.6 | 13.3 | 12.1 | 8.06 |
| Operating Profit | -15 | -12.6 | -11.9 | -11.6 | -8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -15 | -12.6 | -11.9 | -11.6 | -7.95 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -15 | -12.6 | -11.9 | -11.6 | -7.95 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -15 | -12.6 | -11.9 | -11.6 | -7.95 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -15 | -12.6 | -11.9 | -11.6 | -7.95 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -23 | -11.2 | -10.1 | -8.19 | -2.9 |